HUP0401492A2 - R-állapotú inzulin hexamerek cisz-HisB10Zn2+ helyéhez kötődő ligandumok, ezek előállítása, R-állapotú inzulin hexamerek és ilyeneket tartalmazó vizes inzulin készítmények - Google Patents
R-állapotú inzulin hexamerek cisz-HisB10Zn2+ helyéhez kötődő ligandumok, ezek előállítása, R-állapotú inzulin hexamerek és ilyeneket tartalmazó vizes inzulin készítményekInfo
- Publication number
- HUP0401492A2 HUP0401492A2 HU0401492A HUP0401492A HUP0401492A2 HU P0401492 A2 HUP0401492 A2 HU P0401492A2 HU 0401492 A HU0401492 A HU 0401492A HU P0401492 A HUP0401492 A HU P0401492A HU P0401492 A2 HUP0401492 A2 HU P0401492A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- insulin
- groups
- hexamers
- group
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 18
- 102000004877 Insulin Human genes 0.000 title abstract 9
- 108090001061 Insulin Proteins 0.000 title abstract 9
- 229940125396 insulin Drugs 0.000 title abstract 9
- 239000003446 ligand Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 5
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000000732 arylene group Chemical group 0.000 abstract 2
- 125000003636 chemical group Chemical group 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
A találmány tárgyát új ligandumok képezik, amelyek az R-állapotúinzulin hexamer cisz-HisB10Zn2+ helyéhez kapcsolódnak; ezen újligandumok képesek az inzulinkészítmények hatását meghosszabbítani. Atalálmány tárgyához tartoznak továbbá ezen ligandumokat tartalmazó R-állapotú inzulin hexamerek, és ilyen hexamereket tartalmazó vizesinzulinkészítmények is. A találmány tárgyát közelebbről a (lll)általános képletű, cinkhez kötődő ligandumok és azok előállításaképezik, a képletben a szimbólumok jelentése igen sokféle, így példáulA jelentése kémiai csoport, ami reverzibilisen kötődik egy inzulinhexamer HisB10Zn2+ helyéhez; B jelentése kapcsolócsoport az alábbiakközül választva: - vegyértékkötés - GB kémiai csoport, amely -B1B2-C(O)-, -B1B2-S02-, -B1 B2-CH2- vagy B1-B2-NH- általános képletűcsoportot képez, ahol a képletekben B1 jelentése vegyértékkötés; -0-;-S- vagy -NR6-, B2 jelentése vegyértékkötés, alkilén-, alkenilén-,alkinilén-, arilén-, -heteroarilén-, alki1-aril-, -C(=O)-a1ki1-C(=O)-,-C(=O)-alkenil-C(=O)-,-C(=O)-alkil-O-alkil-C(=O)-, -C(=O)-alkil-S-alkil)-C(=O)-, -C(=O)-alkil-NR6=alkil-C(=O)-, -C(=O)-aril-C(=O)-, -C(=O)-heteroaril-C(=O)-; ahol a fentiekben szereplő alkilén-,alkenilén- és alkiniléncsoportok adott esetben szubsztituálva lehetnek-CN, -CF3, -OCF3, -OR6 vagy -NR6R7 csoporttal; az arilén- ésheteroarilén- csoportok adott esetben szubsztituálva lehetnekhalogénatommal, -C(O)OR6, -C(O)H, -OCOR6, -SO2, -CN, -CF3-,-OCF3, -NO2, -OR6, -NR6R7, alkil vagy alkanoilcsoport; R6 és R7 jelentéseegymástól függetlenül hidrogénatom, 1-4 szénatomos alkilcsoport; Cjelentése egy fragmentum, ami 0-5 semleges aminosavból áll, ahol azegyes aminosavak lehetnek azonosak vagy egymástól eltérőek; Djelentése egy fragmentum, ami 1-20 pozitív töltésű csoportból áll;ahol ezen csoportok egymástól függetlenül választhatók, amino- vagyguanidiono-csoportok közül, ahol az egyes pozitív töltésű csoportoklehetnek azonosak vagy egymástól eltérőek; továbbá X jelentése -OH, -NH2 vagy diaminocsoport. A találmány szerinti vegyületek eredményesenalkalmazhatók a vizes inzulinkészítmények hatóanyag-leadásánakmeghosszabbítására. Ó
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101337 | 2001-09-14 | ||
| US32392501P | 2001-09-21 | 2001-09-21 | |
| DKPA200201066 | 2002-07-05 | ||
| US39605102P | 2002-07-10 | 2002-07-10 | |
| PCT/DK2002/000595 WO2003027081A2 (en) | 2001-09-14 | 2002-09-13 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0401492A2 true HUP0401492A2 (hu) | 2004-11-29 |
| HUP0401492A3 HUP0401492A3 (en) | 2008-05-28 |
Family
ID=27439845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0401492A HUP0401492A3 (en) | 2001-09-14 | 2002-09-13 | Novel ligands for the hisb10 zn2+ sites of r-state insulin hexa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7879893B2 (hu) |
| EP (1) | EP1429763B1 (hu) |
| JP (1) | JP4554207B2 (hu) |
| CN (1) | CN1558762A (hu) |
| AT (1) | ATE363278T1 (hu) |
| BR (1) | BR0212522A (hu) |
| CA (1) | CA2460541A1 (hu) |
| CZ (1) | CZ2004313A3 (hu) |
| DE (1) | DE60220424T2 (hu) |
| ES (1) | ES2288195T3 (hu) |
| HU (1) | HUP0401492A3 (hu) |
| MX (1) | MXPA04002404A (hu) |
| NO (1) | NO20041494L (hu) |
| PL (1) | PL369119A1 (hu) |
| WO (1) | WO2003027081A2 (hu) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060606A1 (en) * | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
| US7078423B2 (en) * | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| US20040063098A1 (en) * | 2002-09-26 | 2004-04-01 | Hargreaves John S. | Methods for producing multilayer ligand arrays |
| WO2004043955A1 (en) * | 2002-11-13 | 2004-05-27 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
| ATE378063T1 (de) * | 2002-12-20 | 2007-11-15 | Novo Nordisk As | Pharmazeutische zusammensetzungen mit insulin und insulin-hexamer-liganden |
| US20050065066A1 (en) * | 2002-12-20 | 2005-03-24 | Kaarsholm Niels Christian | Stabilised insulin compositions |
| US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
| US7781464B2 (en) | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
| BRPI0408229A (pt) * | 2003-03-11 | 2006-02-21 | Novo Nordisk As | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação |
| US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
| WO2005005424A1 (en) * | 2003-07-02 | 2005-01-20 | TEVA Gyógyszergyár Részvénytársaság | Aztreonam l-lysine and methods for the preparation thereof |
| US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
| US7037927B2 (en) * | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー／エス | 単鎖インシュリン |
| KR101128065B1 (ko) * | 2004-05-26 | 2012-04-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| MXPA06015049A (es) * | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| EP1768694A1 (en) * | 2004-07-09 | 2007-04-04 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| KR100854864B1 (ko) * | 2004-08-05 | 2008-08-28 | 에프. 호프만-라 로슈 아게 | 인돌, 인다졸 또는 인돌린 유도체 |
| WO2006029634A2 (en) * | 2004-09-17 | 2006-03-23 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
| US7777038B2 (en) * | 2004-09-28 | 2010-08-17 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compound |
| US7923563B2 (en) | 2004-10-26 | 2011-04-12 | Eisai R&D Management Co., Ltd. | Amorphous object of cinnamide compound |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| TW200800978A (en) * | 2006-03-23 | 2008-01-01 | Otsuka Pharma Co Ltd | Carbazole compound |
| JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
| US20080207900A1 (en) | 2007-02-28 | 2008-08-28 | Teiji Kimura | Two cyclic oxomorphorin derivatives |
| CA2694401C (en) | 2007-08-31 | 2012-12-04 | Eisai R&D Management Co., Ltd. | Polycyclic compound |
| US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
| CN104125948A (zh) | 2012-02-21 | 2014-10-29 | 拜耳知识产权有限责任公司 | 具有除草活性的4-硝基-取代的n-(四唑-5-基)芳基羧酸酰胺、n-(三唑-5-基)芳基羧酸酰胺以及n-(1,3,4-噁二唑-2-基)芳基羧酸酰胺 |
| US9447069B2 (en) * | 2012-04-30 | 2016-09-20 | Innov17 Llc | ROR modulators and their uses |
| KR101942752B1 (ko) * | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| JP6156845B2 (ja) * | 2014-03-04 | 2017-07-05 | 株式会社島津製作所 | マトリックス支援レーザ脱離イオン化質量分析用マトリックス |
| AU2015360416A1 (en) * | 2014-12-10 | 2017-06-08 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| EP3282846A4 (en) * | 2015-03-23 | 2018-09-26 | University of Miami | Inhibitors of the notch transcriptional activation complex and methods for use of the same |
| KR20180107261A (ko) | 2016-02-16 | 2018-10-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Myc 조정제로서의 MAX 결합제 및 그의 용도 |
| EP3475264A4 (en) * | 2016-06-28 | 2020-04-15 | University Of Kentucky Research Foundation | PROSTAGLANDIN E-SYNTHASE INHIBITORS AND METHOD FOR USE THEREOF |
| WO2018110669A1 (en) * | 2016-12-15 | 2018-06-21 | Ono Pharmaceutical Co., Ltd. | Activator of trek (twik related k+ channels) channels |
| KR20210020865A (ko) * | 2018-03-16 | 2021-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 | 퍼옥시솜 증식자-활성화 수용체 알파의 효능제 및 사용 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP1982004086A (es) | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
| US5646120A (en) * | 1990-10-24 | 1997-07-08 | Allelix Biopharmaceuticals, Inc. | Peptide-based inhibitors of HIV replication |
| US5830999A (en) | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| DE69914934T2 (de) * | 1998-11-18 | 2005-01-05 | Novo Nordisk A/S | Stabile, wässrige insulin-präparate ohne phenol und cresol |
-
2002
- 2002-09-13 BR BR0212522-6A patent/BR0212522A/pt not_active IP Right Cessation
- 2002-09-13 US US10/332,541 patent/US7879893B2/en not_active Expired - Fee Related
- 2002-09-13 DE DE60220424T patent/DE60220424T2/de not_active Expired - Lifetime
- 2002-09-13 ES ES02774468T patent/ES2288195T3/es not_active Expired - Lifetime
- 2002-09-13 AT AT02774468T patent/ATE363278T1/de not_active IP Right Cessation
- 2002-09-13 EP EP02774468A patent/EP1429763B1/en not_active Expired - Lifetime
- 2002-09-13 CZ CZ2004313A patent/CZ2004313A3/cs unknown
- 2002-09-13 PL PL02369119A patent/PL369119A1/xx not_active Application Discontinuation
- 2002-09-13 CA CA002460541A patent/CA2460541A1/en not_active Abandoned
- 2002-09-13 CN CNA028203402A patent/CN1558762A/zh active Pending
- 2002-09-13 HU HU0401492A patent/HUP0401492A3/hu unknown
- 2002-09-13 MX MXPA04002404A patent/MXPA04002404A/es not_active Application Discontinuation
- 2002-09-13 WO PCT/DK2002/000595 patent/WO2003027081A2/en active IP Right Grant
- 2002-09-13 JP JP2003530671A patent/JP4554207B2/ja not_active Expired - Fee Related
-
2004
- 2004-04-13 NO NO20041494A patent/NO20041494L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2288195T3 (es) | 2008-01-01 |
| HUP0401492A3 (en) | 2008-05-28 |
| CZ2004313A3 (cs) | 2004-07-14 |
| EP1429763B1 (en) | 2007-05-30 |
| PL369119A1 (en) | 2005-04-18 |
| BR0212522A (pt) | 2004-08-10 |
| NO20041494L (no) | 2004-04-13 |
| CA2460541A1 (en) | 2003-04-03 |
| MXPA04002404A (es) | 2004-05-31 |
| DE60220424D1 (de) | 2007-07-12 |
| CN1558762A (zh) | 2004-12-29 |
| EP1429763A2 (en) | 2004-06-23 |
| WO2003027081A2 (en) | 2003-04-03 |
| DE60220424T2 (de) | 2008-03-06 |
| US7879893B2 (en) | 2011-02-01 |
| WO2003027081A3 (en) | 2004-03-25 |
| US20030229120A1 (en) | 2003-12-11 |
| JP2005508335A (ja) | 2005-03-31 |
| JP4554207B2 (ja) | 2010-09-29 |
| ATE363278T1 (de) | 2007-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0401492A2 (hu) | R-állapotú inzulin hexamerek cisz-HisB10Zn2+ helyéhez kötődő ligandumok, ezek előállítása, R-állapotú inzulin hexamerek és ilyeneket tartalmazó vizes inzulin készítmények | |
| Nelsestuen et al. | Interaction of vitamin K dependent proteins with membranes | |
| Marcum et al. | Control of microtubule assembly-disassembly by calcium-dependent regulator protein. | |
| Cao et al. | A novel oligopeptide simulating dentine matrix protein 1 for biomimetic mineralization of dentine | |
| MX9600618A (es) | Composicion dental y metodo. | |
| HRP20221135T1 (hr) | KOMBINACIJE mRNK KOJE KODIRAJU IMUNOMODULIRAJUĆE POLIPEPTIDE I NJIHOVE UPOTREBE | |
| ATE429448T1 (de) | Peptidzusammensetzung als immunogen zur allergiebehandlung. | |
| JP2005538057A5 (hu) | ||
| Ding et al. | Remineralization of enamel caries by an amelogenin-derived peptide and fluoride in vitro | |
| BR9910089A (pt) | Composições e antìgenos de neisseria meningitidis | |
| DE60232790D1 (de) | Dentale zusammensetzung zur behandlung überempfindlicher zähne | |
| IL232501A (en) | Peptide or polypeptide-resistant protein analogs and their uses | |
| TW200500383A (en) | Mixtures of compounds having two or more double bonds and use thereof | |
| DE60133323D1 (de) | Cardioprotektive Phosphonate | |
| WO2004024097A8 (en) | Compositions and methods for the treatment of immune related diseases | |
| RU2014112343A (ru) | Оставы антигенов staphylococcus aureus, содержащие адъюванты | |
| ATE350049T1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
| ATE392922T1 (de) | Verwendungen eines getränks enthaltend ein polyphosphat zur behandlung von zahnerosionen | |
| ATE258598T1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| DE602004025265D1 (de) | Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon | |
| DE60327811D1 (de) | Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen | |
| JP2023093524A (ja) | 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 | |
| AU4011300A (en) | Compositions and methods for the treatment of immune related diseases | |
| Fujisawa et al. | Changes in interaction of bovine dentin phosphophoryn with calcium and hydroxyapatite by chemical modifications | |
| ATE192490T1 (de) | Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |